

Methionin-low diet in acute leukemia patients, a phase I pilot

Published: 27-05-2020

Last updated: 08-04-2024

Safety of a methionine-low diet in patients with AML

| | |
|------------------------------|----------------|
| Ethical review | Not approved |
| Status | Will not start |
| Health condition type | Leukaemias |
| Study type | Interventional |

Summary

ID

NL-OMON49508

Source

ToetsingOnline

Brief title

Methionin-low diet in acute leukemia patients

Condition

- Leukaemias

Synonym

Acute leukemia, blood cancer

Research involving

Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum Groningen

Source(s) of monetary or material Support: stichting hemato onco

Intervention

Keyword: Diet, Leukemia, Methionin, Restriction

Outcome measures

Primary outcome

The safety will be analysed by the occurrence of (S)AE

Secondary outcome

The effectiveness will be measured in the level of leukaemia blasts and the methionine-levels in plasma.

Study description

Background summary

Leukemia cells have an increased need for methionine. Depletion of methionine in vitro is toxic to leukemia cells but not to healthy cells. Previous phase I and II studies show little to no side effects from a methionine-low diet in humans. In this study, we aim to explore the safety and effectiveness of a methionine-low diet in patients with AML

Study objective

Safety of a methionine-low diet in patients with AML

Study design

Human experimental study (phase 1 pilot)

Intervention

A Methionine-low diet, first by tube feeding, then by regular oral food products

Study burden and risks

Aspiration pneumonia in tube feeding
Bleeding and pain from bone marrow puncture and blood sampling
Weight loss and malnutrition
Limitation in own diet

Contacts

Public

Universitair Medisch Centrum Groningen

Hanzeplein 1
Groningen 9713 GZ
NL

Scientific

Universitair Medisch Centrum Groningen

Hanzeplein 1
Groningen 9713 GZ
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Acute myeloid leukemia

Adult

Exclusion criteria

Acute promyelocytic leukemia
medical indication for other diet

Study design

Design

Study type: Interventional

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Will not start

Enrollment: 5

Type: Anticipated

Ethics review

Not approved

Date: 27-05-2020

Application type: First submission

Review commission: METC Universitair Medisch Centrum Groningen (Groningen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register

CCMO

ID

NL73144.042.20